Company Directory / biotech/health
PrivateFor profitbiotech/healthHanover, Germany
Cardior Pharmaceuticals
Cardior Pharmaceuticals discovers and develops medicines and therapeutics for the treatment and prevention of heart disease.
- Founded
- 2016 10 years ago
- Staff
- 11-50 band, as listed
- Followers
- - on LinkedIn
- Funding
- $80M as listed, currency not stated
Set against six million companies
Size
11-50 people: larger than 33% of companies with a size listed
Age
10 years old.
Reach
Website ranked #4,691,561 in the world for traffic, about 2k visits a month.
What it does
BiopharmaBiotechnologyPharmaceutical
Funding, as listed
$80M currency not stated
- Rounds3
- LatestSeries b, Aug 2021
- Investors10, 2 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Cardior Pharmaceuticals, field by field. Contact details are held but never shown.
The company
- Name
- Cardior Pharmaceuticals
- Type
- For profit
- Status
- Private
- Founded
- 2016
- Founders
- Claudia Ulbrich, Thomas Thum
- Industry
- biotech/health
- Categories
- Biopharma, Biotechnology, Pharmaceutical
Where
- City
- Hanover
- Country
- Germany
- Markets
- European Union (EU), Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 11-50
- Web traffic rank
- #4,691,561
- Monthly web visits
- 1,986
Funding, as listed
- Total
- 80,010,000 (currency not stated)
- Rounds
- 3
- Latest round
- Series b
- Latest round date
- Aug 2021
- Investors
- 10
- Lead investors
- 2
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Cardior Pharmaceuticals may be growing as evidenced by the acquisition by Novo Nordisk for a deal worth up to €1 billion, which indicates a significant valuation and investment into the company. The acquisition is aimed at boosting Novo Nordisk's cardiovascular pipeline, suggesting that Cardior Pharmaceuticals' assets, including its RNA-based heart disease therapies, are valuable additions to Novo Nordisk's portfolio. Furthermore, the deal to acquire Cardior Pharmaceuticals for $1.1 billion underscores the financial strength and market confidence in Cardior's potential within the cardiovascular disease sector.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
biotech/health in Germany.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 106,645 companies in Germany and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.